Day One Biopharmaceuticals Stock Performance
| DAWN Stock | USD 8.04 0.00 0.00% |
The firm shows a Beta (market volatility) of -0.0745, which means not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Day One are expected to decrease at a much lower rate. During the bear market, Day One is likely to outperform the market. At this point, Day One Biopharmaceu has a negative expected return of -0.64%. Please make sure to confirm Day One's maximum drawdown, rate of daily change, as well as the relationship between the Rate Of Daily Change and relative strength index , to decide if Day One Biopharmaceu performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Day One Biopharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in April 2025. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more
Actual Historical Performance (%)
One Day Return (0.36) | Five Day Return 0.61 | Year To Date Return (34.85) | Ten Year Return (64.77) | All Time Return (64.77) |
1 | Acquisition by Adam Dubow of 59000 shares of Day One subject to Rule 16b-3 | 01/15/2025 |
2 | Disposition of 2675 shares by York Charles N Ii of Day One at 16.0787 subject to Rule 16b-3 | 01/17/2025 |
3 | Why Is Andreas Halvorsen Bullish On Day One Biopharmaceuticals, Inc. Now | 01/23/2025 |
4 | Disposition of 12048 shares by Bender Jeremy of Day One at 11.963 subject to Rule 16b-3 | 02/18/2025 |
5 | BioMarin Q4 Earnings Sales Top Estimates, Stock Up on Upbeat 25 View | 02/20/2025 |
6 | Day One Biopharmaceuticals Q4 2024 Earnings Preview | 02/24/2025 |
7 | DAWN chiede alla Corte penale internazionale di indagare sullamministrazione Biden per favoreggiamento e complicit nei crimini israeliani a Gaza | 02/25/2025 |
8 | Insider Trading | 02/26/2025 |
9 | What is Wedbushs Forecast for DAWN Q1 Earnings | 02/28/2025 |
10 | JPMorgan Chase Co. Lowers Day One Biopharmaceuticals Price Target to 34.00 - Defense World | 03/06/2025 |
11 | Disposition of 2206 shares by Blackman Samuel C. of Day One at 13.2102 subject to Rule 16b-3 | 03/14/2025 |
12 | Disposition of 30000 shares by Blackman Samuel C. of Day One at 13.3113 subject to Rule 16b-3 | 03/21/2025 |
| Begin Period Cash Flow | 230.8 M |
Day |
Day One Relative Risk vs. Return Landscape
If you would invest 1,290 in Day One Biopharmaceuticals on December 26, 2024 and sell it today you would lose (459.00) from holding Day One Biopharmaceuticals or give up 35.58% of portfolio value over 90 days. Day One Biopharmaceuticals is currently does not generate positive expected returns and assumes 4.289% risk (volatility on return distribution) over the 90 days horizon. In different words, 38% of stocks are less volatile than Day, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Day One Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Day One's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Day One Biopharmaceuticals, and traders can use it to determine the average amount a Day One's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1488
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | DAWN |
Estimated Market Risk
| 4.29 actual daily | 38 62% of assets are more volatile |
Expected Return
| -0.64 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.15 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Day One is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Day One by adding Day One to a well-diversified portfolio.
Day One Fundamentals Growth
Day Stock prices reflect investors' perceptions of the future prospects and financial health of Day One, and Day One fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Day Stock performance.
| Return On Equity | -0.22 | ||||
| Return On Asset | -0.28 | ||||
| Profit Margin | (0.73) % | ||||
| Operating Margin | (2.24) % | ||||
| Current Valuation | 313.14 M | ||||
| Shares Outstanding | 101.36 M | ||||
| Price To Earning | 3.88 X | ||||
| Price To Book | 1.68 X | ||||
| Price To Sales | 6.40 X | ||||
| Revenue | 131.16 M | ||||
| Gross Profit | 125.88 M | ||||
| EBITDA | (217.27 M) | ||||
| Net Income | (95.5 M) | ||||
| Cash And Equivalents | 394.86 M | ||||
| Cash Per Share | 5.38 X | ||||
| Total Debt | 2.6 M | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 31.45 X | ||||
| Book Value Per Share | 4.97 X | ||||
| Cash Flow From Operations | (78.11 M) | ||||
| Earnings Per Share | (1.02) X | ||||
| Market Capitalization | 839.22 M | ||||
| Total Asset | 582.79 M | ||||
| Retained Earnings | (554.08 M) | ||||
| Working Capital | 488.88 M | ||||
About Day One Performance
By examining Day One's fundamental ratios, stakeholders can obtain critical insights into Day One's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Day One is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 206.66 | 183.70 | |
| Return On Tangible Assets | (0.17) | (0.18) | |
| Return On Capital Employed | (0.43) | (0.45) | |
| Return On Assets | (0.16) | (0.17) | |
| Return On Equity | (0.19) | (0.18) |
Things to note about Day One Biopharmaceu performance evaluation
Checking the ongoing alerts about Day One for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Day One Biopharmaceu help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Day One Biopharmaceu generated a negative expected return over the last 90 days | |
| Day One Biopharmaceu has high historical volatility and very poor performance | |
| Day One Biopharmaceu has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 131.16 M. Net Loss for the year was (95.5 M) with profit before overhead, payroll, taxes, and interest of 125.88 M. | |
| Day One Biopharmaceuticals currently holds about 394.86 M in cash with (78.11 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.38. | |
| Day One Biopharmaceu has a frail financial position based on the latest SEC disclosures | |
| Over 95.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from MacroaxisInsider: Disposition of 2206 shares by Blackman Samuel C. of Day One at 13.2102 subject to Rule 16b-3 |
- Analyzing Day One's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Day One's stock is overvalued or undervalued compared to its peers.
- Examining Day One's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Day One's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Day One's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Day One's stock. These opinions can provide insight into Day One's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Day One Biopharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Day One. If investors know Day will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Day One listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Day One Biopharmaceu is measured differently than its book value, which is the value of Day that is recorded on the company's balance sheet. Investors also form their own opinion of Day One's value that differs from its market value or its book value, called intrinsic value, which is Day One's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Day One's market value can be influenced by many factors that don't directly affect Day One's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Day One's value and its price as these two are different measures arrived at by different means. Investors typically determine if Day One is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Day One's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.